NZ201067A - Collagen implant containing pharmacologically active material - Google Patents
Collagen implant containing pharmacologically active materialInfo
- Publication number
- NZ201067A NZ201067A NZ201067A NZ20106782A NZ201067A NZ 201067 A NZ201067 A NZ 201067A NZ 201067 A NZ201067 A NZ 201067A NZ 20106782 A NZ20106782 A NZ 20106782A NZ 201067 A NZ201067 A NZ 201067A
- Authority
- NZ
- New Zealand
- Prior art keywords
- collagen
- active ingredient
- sheet
- pharmacologically active
- gentamycin
- Prior art date
Links
- 239000000501 collagen implant Substances 0.000 title claims description 15
- 239000011149 active material Substances 0.000 title 1
- 102000008186 Collagen Human genes 0.000 claims abstract description 38
- 108010035532 Collagen Proteins 0.000 claims abstract description 38
- 229920001436 collagen Polymers 0.000 claims abstract description 38
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 210000003195 fascia Anatomy 0.000 claims abstract description 6
- 229960002591 hydroxyproline Drugs 0.000 claims abstract description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 3
- 239000002831 pharmacologic agent Substances 0.000 claims description 9
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 8
- 229930182566 Gentamicin Natural products 0.000 claims description 8
- 238000002513 implantation Methods 0.000 claims description 7
- 210000004872 soft tissue Anatomy 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 210000002303 tibia Anatomy 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 229920001577 copolymer Polymers 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- -1 antiseptics Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Collagen insert containing an active ingredient for introduction into bones or soft parts, characterized in that it is prepared by adding to a solution of high-purity native collagen, wherein the collagen has a factor of nitrogen to hydroxyproline =< 3 to 5, a solution or suspension of said active ingredient and then by drying with hot air or by freeze-drying a sheet is produced in the form of a fascia and finally it is optionally wound to form a rod.
Description
<div class="application article clearfix" id="description">
<p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number £01 067 <br><br>
20 <br><br>
1067 <br><br>
lt fcwi-izi DaHs)' 2^-- L~s>) | ' <br><br>
Complete Specification Filed:-^4 <br><br>
Class: . ./^ j ^ Jc>o <br><br>
Publication Date: j?.l MAYjggg r?- JowmaJ, Wo: .'PrT7. I <br><br>
Ni <br><br>
No.: Date: <br><br>
NEW ZEALAND <br><br>
PATENTS ACT, 1953 <br><br>
COMPLETE SPECIFICATION <br><br>
"COLLAGEN IMPLANT CONTAINING ACTIVE INGREDIENT(S) FOR IMPLANTATION IN BONES OR SOFT TISSUES AND PROCESS FOR ITS MANUFACTURE" <br><br>
I3i£We, SCHERING CORPORATION, a corporation organized under and by virtue of the laws of -Hie State of New Jersey, United States of America, of 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States of America, <br><br>
hereby declare the invention for which lc^ we pray that a patent may be granted to and the method by which it is to be performed, <br><br>
to be particularly described in and by the following statement:- <br><br>
- 1 - <br><br>
(followed by page la) <br><br>
201067 <br><br>
- la - <br><br>
Collagen Implant Containing Active Ingredient(s) for Implantation in Bones or Soft Tissues and Process for its Manufacture <br><br>
The invention concerns an implant resorbable in 5 the body and containing active ingredients, for implantation in bones and soft tissues. It especially relates to a collagen implant in the form of a sheet containing pharmacologically active ingredient(s), <br><br>
which optionally can be rolled into a rod and which 10 after implantation in the bone or tissue gradually releases the ingredient(s). <br><br>
It is known that collagen can be used as material which is bioresorbable in the body, for filling defects in bones or in soft tissues. <br><br>
15 The use of polyhydroxy acetic acid ester for the manufacture of antibiotic-containing resorbable surgical materials, e.g. tubes, is known. A combination of an active ingredient with a polylactide or of a copolymer of lactide and glycolide units is 20 also known. <br><br>
The above-mentioned materials are synthetic polymers or copolymers which are decomposed in the body. Such polymers and copolymers have increasingly gained in significance because as fully synthetic 25 products they have readily reproducible properties and can be prepared in high purity. Materials of the above-mentioned polymers and copolymers are also used as synthetic resorbable suture materials. <br><br>
For many years collagen has been known as a <br><br>
30 resorbable material and has been used hemostatically, <br><br>
<?• <br><br>
especially during and after surgical operations or "t^y fill body cavities or to cover wounds. There have , <br><br>
20!067 <br><br>
- 2 - <br><br>
/ <br><br>
always been certain problems concerning the degree of purity of collagen, since it is extracted from natural products, and is difficult to produce in high purity. However, collagen can be made with a high degree of 5 purity, so that complications can be avoided when using it for surgical purposes. <br><br>
A shaped mass resorbable in the body and based on collagen is also known. This shaped mass contains, in addition to denatured collagen, a bioresorbable binding 10 agent as well as optionally an active ingredient. The above-mentioned polymers and copolymers of glycolic acid or of lactide and glycolide are especially suitable as the bioresorbable binding agents. <br><br>
It is the object of this invention to provide a 15 bioresorbable implant containing a pharmacologically active ingredient for implantation in bones or soft tissues. <br><br>
This object has been attained by providing a very pure native collagen containing a pharmacologically 20 active ingredient. The invention therefore provides a collagen implant containing pharmacologically active ingredient(s) for implantation in bones or soft tissues, consisting of highly pure native collagen and having a factor nitrogen: hydroxyprol ine _< 3 to 5 and 25 charged with a pharmacologically active ingredient. <br><br>
The collagen implant can be in the form of a sheet or rod, the rod being made by rolling the collagen sheet. (By the term "native collagen" is meant collagen which is purified but not changed in its 30 structure.) <br><br>
The rod-shaped collagen product has about the same thickness as a pencil. It can be conveniently made by adding a solution of the active ingredient to a collagen solution; after <br><br>
• - 3 - 201 067 <br><br>
j drying; e.g. with hot air or by lyophilization, the collagen is^ first prepared in sheet form (as a so-called fascia) ." <br><br>
Also the reverse route, depending on the stability of the active ingredient, can be undertaken, by first preparing 5 the collagen fascia and then charging it with the active ingredient. This can be done e.g. by spraying an aqueous solution of an active ingredient, e.g. an antibiotic in the form of a salt on the collagen sheet and allowing it to dry there. Equally it is possible to apply the antibio-10 tic or another pharmacologically effective compound, by painting, rolling, dipping or sprinkling with an active ingredient in powder form or in a similar manner. The so obtained collagen sheet charged with the active ingredient can then be rolled into a rod-shaped product of about pencil 15 thickness. In this form it can be cut into any desired length depending on the desired dose and can be packed to remain sterile until used. <br><br>
Especially suitable active ingredients in combination with ■ collagen are aminoglycoside antibiotics, such as gentamycin. <br><br>
In salt form, e.g. as sulfate, gentamycin is , i <br><br>
TO- water-soluble and can be added to the collagen in a wide <br><br>
2 i range from about 1 to about 100 mg/cm fascia or it can be sprayed on. The collagen sheet (collagen fascia) containing the gentamycin can then be rolled and dried and thereafter it maintains its rod-shape. <br><br>
i <br><br>
•26- Other active ingredients such as sulfonamides, antiseptics, or corticosteroids can be added instead of or in addition to the antibiotic. <br><br>
•«- <br><br>
The collagen used has a purity expressed by the factor nitrogen: hydroxy pro line <3 to 5. Such a collagen can be pre- <br><br>
-3©- pared in the manner described in the example. 1 <br><br>
( <br><br>
Using the rod-shaped collagen charged with an active in- <br><br>
• " ■ ■ . 4" <br><br>
1 . ' > <br><br>
. 4 - <br><br>
20106 <br><br>
- 4 - <br><br>
gredient of the invention is of special advantage in that the active ingredient adheres very well to the collagen and optionally can even be bonded to it. To the extent that the collagen decomposes over a period of time, the active 5 ingredient is released/ so that there is a sustained release. A further advantage is that the carrier matrix collagen serves as a guide for proliferating connective tissue cells and thus promotes the healing of the wound in a known manner. <br><br>
10 Example <br><br>
The following highly pure native collagen is prepared as follows: <br><br>
Fresh beef tendons freed from all pigment layers and residues of muscle were homogenised and an amount correspon-15 ding to 100 g dry weight was extracted with 3 liters 0.05 M citrate buffer (pH 3.7) for 24 hours and then dialysed for 12 hours against 1% acetic acid. The tissue, suspended in 3 liters 1% acetic acid, was incubated with constant stirring for 48 hours at 15°C with pepsin in a ratio of collagen 20 to pepsin of 50 : 1. <br><br>
The preparation was diluted with 1% acetic acid to 5 liters and then freed from undissolved tendon fragments by centri-fugation. <br><br>
The viscous collagen solution was dialysed against alkalised 25 tap water (pH 8.0) and was then vigorously centrifuged. The residue was again dissolved in 5 liters 1% acetic acid and dialysed. This process was repeated until the factor nitrogen :hydroxy-proline was J^.3. After the last dialysis a 1.5% collagen solution in 0.05% acetic acid was prepared. <br><br></p>
</div>
Claims (9)
1. Collagen implant containing pharmacologically active ingredient(s) for implantation in bones or soft tissues, consisting of highly pure native collagen<br><br> 5 having a factor nitrogen:hydroxyproline <_ 3 to 5 and charged with a pharmacologically active ingredient.<br><br>
2. Collagen implant according to claim 1 in sheet form.<br><br>
3. Collagen implant according to claim 1 in the form 10 of a sheet rolled into a rod-shaped product.<br><br>
4. Collagen implant according to any one of claims 1 to 3, wherein the active ingredient is an antibiotic.<br><br>
5. Collagen implant according to claim 4 wherein the antibiotic is gentamycin.<br><br> 15
6. Collagen implant containing pharmacologically active ingredient(s) according to claim 1 or 2 prepared, by admixing the active ingredient(s) in a suitable vehicle with a collagen solution and processing after drying into a sheet and then if desired rolling the 20 sheet into a rod.<br><br>
7. Process for the preparation of a collagen implant containing pharmacologically active ingredient(s)<br><br> according to claim 1, characterized in that highly pure native collagen having a factor nitrogen:hydroxyproline 25 <_ 3 to 5 is charged with pharmacologically active ingredient(s), processed into a sheet and optionally<br><br> ' 1/'^<br><br> 201067<br><br> - 7 -<br><br> rolled into a rod.<br><br>
8. An implant as claimed in any one of claims 1 to 6 substantially as hereinabove described with reference to any Example thereof.<br><br> 5
9. A process as claimed in claim 7 when performed substantially as herein described.<br><br> By His/Thai r authorised A. J. PARK & SON<br><br> ftr Xfc>c/.<br><br> </p> </div>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813124981 DE3124981A1 (en) | 1981-06-25 | 1981-06-25 | ACTIVE INGREDIENT COLLAGEN INSERT FOR INSERTION INTO BONES OR SOFT PARTS AND METHOD FOR THEIR PRODUCTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ201067A true NZ201067A (en) | 1985-05-31 |
Family
ID=6135358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ201067A NZ201067A (en) | 1981-06-25 | 1982-06-24 | Collagen implant containing pharmacologically active material |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0069260B1 (en) |
| JP (1) | JPS584551A (en) |
| AT (1) | ATE15763T1 (en) |
| AU (1) | AU555952B2 (en) |
| CA (1) | CA1183776A (en) |
| DE (2) | DE3124981A1 (en) |
| IE (1) | IE53579B1 (en) |
| MX (1) | MX9203310A (en) |
| NZ (1) | NZ201067A (en) |
| ZA (1) | ZA824517B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3409372A1 (en) * | 1984-03-14 | 1985-09-19 | Dr. Ruhland Nachf. GmbH, 8425 Neustadt | Material for the vitalisation of implant surfaces |
| DE3500268A1 (en) * | 1985-01-05 | 1986-07-10 | Hoechst Ag, 6230 Frankfurt | PREPARATIONS WITH DELAYED EFFECT, METHOD FOR THE PRODUCTION THEREOF AND CORRESPONDING AGENTS FOR THE HUMAN OR. VETERINE MEDICAL APPLICATION |
| DE3533369A1 (en) * | 1985-09-19 | 1987-03-19 | Alois Prof Dr Med Bloemer | ANTIBIOTIC CONTAINER AND ITS USE AS SURGICAL PLASTIC MATERIAL |
| US4865602A (en) * | 1986-11-06 | 1989-09-12 | Collagen Corporation | Gamma irradiation of collagen/mineral mixtures |
| NL8701370A (en) * | 1987-06-12 | 1987-08-03 | Stichting Surgical Research Fo | Chamois leather as an adhesive for living tissues. |
| AP105A (en) * | 1987-12-11 | 1990-11-07 | Geo Schwulst Laboratories Ltd | Treatment of animals. |
| US5354557A (en) * | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US6919308B2 (en) | 1988-04-08 | 2005-07-19 | Stryker Corporation | Osteogenic devices |
| US5162114A (en) * | 1989-02-23 | 1992-11-10 | Stryker Corporation | Bone collagen matrix for xenogenic implants |
| US4975526A (en) * | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5447966A (en) * | 1988-07-19 | 1995-09-05 | United States Surgical Corporation | Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin |
| US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
| ATE139126T1 (en) * | 1990-09-10 | 1996-06-15 | Synthes Ag | MEMBRANE FOR BONE REGENERATION |
| DE9203684U1 (en) * | 1992-03-19 | 1992-07-02 | Pohl, Yango, 61231 Bad Nauheim | Device for root resection |
| IL105529A0 (en) * | 1992-05-01 | 1993-08-18 | Amgen Inc | Collagen-containing sponges as drug delivery for proteins |
| US5733884A (en) | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
| DE19739031A1 (en) * | 1997-09-05 | 1999-03-11 | Suwelack Nachf Dr Otto | Oral administration agent, its preparation and use |
| DE19962248A1 (en) | 1999-12-22 | 2001-06-28 | Tutogen Medical Gmbh | Producing bone material containing bone morphogenic protein, useful as transplant for accelerating bone growth, includes resorbable material for sustained release of protein |
| USRE47826E1 (en) | 2007-03-28 | 2020-01-28 | Innocoll Pharmaceuticals Limited | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
| US8034368B2 (en) | 2007-03-28 | 2011-10-11 | Innocoll Technologies Limited | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
| JP5945380B2 (en) * | 2008-12-09 | 2016-07-05 | Hoya株式会社 | Absorption-replacement type artificial bone and manufacturing method thereof |
| FR2940620B1 (en) * | 2008-12-26 | 2012-03-30 | Hoya Corp | ARTIFICIAL BONE THAT CAN BE REPLACED AND REPLACED BY AN AUTOGENOUS BONE AND METHOD FOR ITS PRODUCTION |
| EP2510929A1 (en) * | 2011-04-11 | 2012-10-17 | Innocoll Technologies Limited | Methods for treating bacterial infection |
| EP2574349A1 (en) | 2011-09-29 | 2013-04-03 | Biorigen S.r.l | Therapeutic use of gelatin hydrogels with a gel-sol transition at body temperature |
| WO2013045689A1 (en) | 2011-09-29 | 2013-04-04 | BIORIGEN Srl | Therapeutic use of gelatin hydrogels with a gel-sol transition at body temperature |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) * | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
| CH627078A5 (en) * | 1975-06-05 | 1981-12-31 | Pentapharm Ag | Process for the preparation of a sterile collagen product with felt-like or web-like fibre structure |
| JPS5842473B2 (en) * | 1975-09-02 | 1983-09-20 | シャープ株式会社 | Hakumaku EL Soshino Kudohouhou |
| SU736374A1 (en) * | 1977-06-06 | 1980-05-25 | Предприятие П/Я Р-6517 | Method and device for dc cutout |
| DE2815934A1 (en) * | 1978-04-13 | 1979-10-25 | Merck Patent Gmbh | Surgical pegs for insertion into bone - consisting of a plastic and an antibacterial e.g. gentamycin |
| GB1565340A (en) * | 1978-04-25 | 1980-04-16 | Grant R A | Fibrous tussue preparations |
| DE2854490C2 (en) * | 1978-12-16 | 1981-04-09 | B. Braun Melsungen Ag, 3508 Melsungen | Bone substitute material with improved biological stability based on collagen |
| US4279812A (en) * | 1979-09-12 | 1981-07-21 | Seton Company | Process for preparing macromolecular biologically active collagen |
-
1981
- 1981-06-25 DE DE19813124981 patent/DE3124981A1/en not_active Withdrawn
-
1982
- 1982-06-18 AT AT82105341T patent/ATE15763T1/en not_active IP Right Cessation
- 1982-06-18 EP EP82105341A patent/EP0069260B1/en not_active Expired
- 1982-06-18 DE DE8282105341T patent/DE3266525D1/en not_active Expired
- 1982-06-24 NZ NZ201067A patent/NZ201067A/en unknown
- 1982-06-24 ZA ZA824517A patent/ZA824517B/en unknown
- 1982-06-24 AU AU85177/82A patent/AU555952B2/en not_active Expired
- 1982-06-24 IE IE1514/82A patent/IE53579B1/en not_active IP Right Cessation
- 1982-06-25 CA CA000406019A patent/CA1183776A/en not_active Expired
- 1982-06-25 JP JP57109695A patent/JPS584551A/en active Granted
-
1992
- 1992-06-25 MX MX9203310A patent/MX9203310A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE15763T1 (en) | 1985-10-15 |
| JPH0118744B2 (en) | 1989-04-07 |
| DE3266525D1 (en) | 1985-10-31 |
| AU555952B2 (en) | 1986-10-16 |
| JPS584551A (en) | 1983-01-11 |
| ZA824517B (en) | 1983-04-27 |
| AU8517782A (en) | 1983-01-06 |
| MX9203310A (en) | 1992-07-01 |
| EP0069260A3 (en) | 1983-06-22 |
| DE3124981A1 (en) | 1983-01-13 |
| IE53579B1 (en) | 1988-12-21 |
| CA1183776A (en) | 1985-03-12 |
| IE821514L (en) | 1982-12-25 |
| EP0069260A2 (en) | 1983-01-12 |
| EP0069260B1 (en) | 1985-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ201067A (en) | Collagen implant containing pharmacologically active material | |
| US5433751A (en) | Bone prosthesis material containing calcium carbonate particles dispersed in a bioresorbable polymer matrix | |
| EP0234004B1 (en) | Implantable pharmaceutical depot composition containing gyrase inhibitors | |
| US5447966A (en) | Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin | |
| DE69726769T2 (en) | BIODRODIBLE ADHESIVES FOR TISSUE RECOVERY | |
| US5139527A (en) | Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation | |
| EP0888140B1 (en) | Coated bioabsorbable beads for wound treatment | |
| US6110205A (en) | Implant material having an excipient/active compound combination | |
| JP3727059B2 (en) | Method for producing porous composite material | |
| JP2003093495A (en) | Alternate bone material charged with fibroblast growth factor | |
| CN108135702B (en) | Implants with oxysterol drug loading and methods of use | |
| JPH07277992A (en) | Delayed release administration molded material containing palmitic acid clindamycin | |
| JP2003501217A (en) | Biomaterials based on insolubilized dextran derivatives and growth factors | |
| US5263985A (en) | Bone growth stimulator | |
| US5819748A (en) | Implant for use in bone surgery | |
| JPH07500990A (en) | How to use biomaterials for tissue repair | |
| JPH06225894A (en) | Hollow internal protease with filler to promote growth of bone | |
| KR101536897B1 (en) | Bioresorbable polymer matrices and methods of making and using the same | |
| JP2001521414A (en) | Implantable putty-like material | |
| CA2004166C (en) | Implant for use in bone surgery | |
| JP2001512344A (en) | Bone replacement material having surface coating of peptide having RGD amino acid sequence | |
| CA1333050C (en) | Biologic absorbable implant material for filling and closing soft-tissue cavities and method of its preparation | |
| Feldman et al. | Compatibility of autologous fibrin adhesive with implant materials | |
| IE69125B1 (en) | Bone growth stimulator | |
| EP0585476A1 (en) | Method and composition for treating bioabsorbable surgical articles |